Loading
SDHB (Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Breast cancer and Gastrointestinal stromal tumour.
Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q). SDH also oxidises malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate. Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerised into keto-oxaloacetate.
CIViC holds 3 clinical evidence items and 0 assertions across 4 variants, naming Vandetanib and Metformin. Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.98, affected pathway 0.32, genetic association 0.61, somatic mutation 0.96).
In plain words · SDHB (Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Breast cancer and Gastrointestinal stromal tumour.
SDHB (Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial) is an enzyme. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Neuroendocrine tumours, Breast cancer and Gastrointestinal stromal tumour.
Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q).
No product in this corpus aims at SDHB yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA SDHB: RNA tissue enhanced (skeletal muscle 461 nTPM, tongue 542 nTPM); high antibody staining in 29 normal tissues; highest cancer staining colorectal cancer (11 of 12 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Neuroendocrine tumours, Breast cancer (all types), Sarcomas (soft tissue, bone, GIST)); Open Targets associates it with 6 specific cancer types at or above 0.5 (pheochromocytoma/paraganglioma syndrome 4, hereditary pheochromocytoma-paraganglioma, Carney-Stratakis syndrome, pheochromocytoma, gastrointestinal stromal tumor, hereditary neoplastic syndrome). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas SDHB tissue; Open Targets ENSG00000117118 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Gould S.J. et al, Proc. Natl. Acad. Sci. U.S.A, 1989, "Use of the DNA polymerase chain reaction for homology probing: isolation of partial cDNA or genomic clones encoding the iron-sulfur protein of succinate dehydrogenase from several species". Source.
Sources: HGNC HGNC:10681 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P21912 (protein name, function text, keywords and locations (REST API)); CIViC gene SDHB (3 evidence items, 0 assertions, 4 variants; diseases: Paraganglioma, Hereditary Renal Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000117118 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: neuroendocrine neoplasm 0.88, gastrointestinal stromal tumour 0.75, breast cancer 0.54 (GraphQL API, CC0))
Iron-sulfur protein (IP) subunit of the succinate dehydrogenase complex (mitochondrial respiratory chain complex II), responsible for transferring electrons from succinate to ubiquinone (coenzyme Q). SDH also oxidises malate to the non-canonical enol form of oxaloacetate, enol-oxaloacetate. Enol-oxaloacetate, which is a potent inhibitor of the succinate dehydrogenase activity, is further isomerised into keto-oxaloacetate. Location: Mitochondrion inner membrane (UniProt). Locus 1p36.13 (HGNC).
RNA: tissue enhanced (skeletal muscle 461 nTPM, tongue 542 nTPM), detected in all normal tissues.
Medium: Bone marrow, Cervix, Epididymis, Fallopian tube, Oral mucosa, Ovary, Placenta, Prostate.
Medium only: cervical cancer, head and neck cancer, renal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SDHB" OR ABSTRACT:"SDHB" OR TITLE:"succinate dehydrogenase complex iron sulfur subunit B" OR ABSTRACT:"succinate dehydrogenase complex iron sulfur subunit B" OR TITLE:"Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial" OR ABSTRACT:"Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial" OR TITLE:"SDH1" OR ABSTRACT:"SDH1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SDHB, not a curated reading list.
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours, Breast cancer (all types), Open Targets Platform.
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours, CIViC, Open Targets Platform.
Shares Gastrointestinal stromal tumour (GIST), Neuroendocrine tumours, Breast cancer (all types), Open Targets Platform.
Shares Gastrointestinal stromal tumour (GIST), Open Targets Platform.